Pirmenol, a new class I antiarrhythmic drug, was given for the treatment of frequent premature ventricular complexes (PVCs) over a 6-month period. Ten patients who had their arrhythmia effectively suppressed by pirmenol in a dose-ranging study were treated with the lowest effective doses in an open investigation. The mean daily doses were 315 mg at the beginning and 340 mg at the end of 6 months. The mean reduction in the frequency of PVC/h remained between 85.5 and 88.6% during 24-h ambulatory electrocardiogram recordings at 1, 3, 5, and 6 months of therapy. With adjustment of the dosage, the predetermined efficacy criteria were fulfilled by eight to 10 patients at each of the four assessments. The PVC/h or repetitive PVC/h frequencies of the patient group did not decline spontaneously within 6 months of treatment, as shown in a placebo control phase. No aggravation of arrhythmias was observed. Side effects in two patients did not prevent prolonged use.

Anti-Arrhythmia Agents↗

PubMedDate not supplied

A two-year circulatory follow-up of physical training after myocardial infarction.

Explore the source record for details and available documents.

Adult↗

PubMedDate not supplied

Prevention of early reocclusion by dipyridamole and ASA in arterial reconstructive surgery.

In this prospective study 364 patients were subjected to different types of arterial reconstructive surgery. The patients were randomly divided into four groups according to the type of antithrombotic medication given. During the hospitalization period there were no reocclusions in the dipyridamole/ASA group of 93 patients compared with 12 reocclusions in the control group of 86 patients. The difference was statistically highly significant. The difference between the control group and the given dipyridamole or ASA was not statistically significant. Dipyridamole and ASA were tolerated well by the patients in this clinical trial. This was the first clinical investigation to prove the effectiveness of dipyridamole and ASA medication in the prevention of reocclusions in arterial reconstructive bypass surgery.

Arterial Occlusive Diseases↗

PubMedDate not supplied

Prevention of deep venous thrombosis and thrombo-embolism by dipyridamole and acetylsalicylic acid after reconstructive arterial surgery.

A series of 400 consecutive patients subjected to reconstructive arterial surgery were randomly allocated into four equal groups in order to study the effect of dipyridamole and acetylsalicylic acid (ASA) in the prevention of deep venous thrombosis and pulmonary embolism. There were 11 drop-outs. In the dipyridamole-ASA group there were no thrombotic complications while in the control group without antithrombotic therapy five cases of deep venous thrombosis and two cases of fatal pulmonary embolism were encountered (p < 0.05). In the groups receiving either dipyridamole or ASA alone two and four cases of deep venous thrombosis, respectively, were found. It is concluded that treatment with dipyridamole and ASA combined is useful in preventing postoperative thrombotic complication after peripheral vascular reconstructive surgery.

Adolescent↗